Natixis Advisors, L.P. Gilead Sciences, Inc. Transaction History

Natixis Advisors, L.P.

$51.3 Billion
Q3 2024

A detailed history of Natixis Advisors, L.P. transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Natixis Advisors, L.P. holds 169,363 shares of GILD stock, worth $15.3 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

169,363

Previous 143,451 18.06%

Holding current value

$15.3 Million

Previous $9.84 Million 44.27%

% of portfolio

0.03%

Previous 0.02%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 06, 2024	BUY	$66.59 - $83.99 $1.73 Million - $2.18 Million	25,912 Added 18.06%	169,363 $14.2 Million
Q2 2024 Aug 01, 2024	SELL	$63.15 - $72.88 $2.27 Million - $2.62 Million	-35,988 Reduced 20.06%	143,451 $9.84 Million
Q1 2024 Apr 25, 2024	SELL	$71.58 - $87.29 $7.17 Million - $8.74 Million	-100,181 Reduced 35.83%	179,439 $13.1 Million
Q4 2023 Feb 06, 2024	BUY	$73.27 - $83.09 $2.69 Million - $3.05 Million	36,711 Added 15.11%	279,620 $22.7 Million
Q3 2023 Nov 13, 2023	SELL	$73.94 - $80.67 $153,943 - $167,954	-2,082 Reduced 0.85%	242,909 $18.2 Million
Q2 2023 Aug 15, 2023	SELL	$76.01 - $86.7 $730,456 - $833,187	-9,610 Reduced 3.77%	244,991 $18.9 Million
Q1 2023 May 11, 2023	BUY	$77.31 - $88.08 $4.6 Million - $5.24 Million	59,489 Added 30.49%	254,601 $21.1 Million
Q4 2022 Jan 27, 2023	BUY	$62.32 - $89.47 $2.23 Million - $3.2 Million	35,725 Added 22.41%	195,112 $16.8 Million
Q3 2022 Nov 14, 2022	BUY	$59.54 - $68.01 $1.37 Million - $1.56 Million	22,941 Added 16.81%	159,387 $9.83 Million
Q2 2022 Aug 12, 2022	BUY	$57.72 - $65.01 $3.93 Million - $4.43 Million	68,104 Added 99.65%	136,446 $8.43 Million
Q1 2022 May 12, 2022	SELL	$57.92 - $72.58 $5.66 Million - $7.09 Million	-97,689 Reduced 58.84%	68,342 $4.06 Million
Q4 2021 Feb 08, 2022	BUY	$64.88 - $73.64 $1.58 Million - $1.79 Million	24,324 Added 17.16%	166,031 $12.1 Million
Q3 2021 Nov 15, 2021	BUY	$67.69 - $73.03 $246,391 - $265,829	3,640 Added 2.64%	141,707 $9.9 Million
Q2 2021 Aug 12, 2021	BUY	$63.47 - $69.35 $1.76 Million - $1.92 Million	27,658 Added 25.05%	138,067 $9.51 Million
Q1 2021 May 05, 2021	BUY	$60.0 - $68.46 $1.47 Million - $1.68 Million	24,550 Added 28.59%	110,409 $7.14 Million
Q4 2020 Feb 12, 2021	SELL	$56.65 - $64.55 $903,057 - $1.03 Million	-15,941 Reduced 15.66%	85,859 $5 Million
Q3 2020 Nov 12, 2020	SELL	$62.1 - $78.08 $4.16 Million - $5.23 Million	-66,944 Reduced 39.67%	101,800 $6.43 Million
Q2 2020 Aug 11, 2020	SELL	$72.34 - $84.0 $1.35 Million - $1.57 Million	-18,688 Reduced 9.97%	168,744 $13 Million
Q1 2020 Apr 27, 2020	BUY	$62.63 - $80.22 $6.09 Million - $7.8 Million	97,251 Added 107.84%	187,432 $14 Million
Q4 2019 Feb 10, 2020	SELL	$61.62 - $67.78 $443,232 - $487,541	-7,193 Reduced 7.39%	90,181 $5.86 Million
Q3 2019 Nov 12, 2019	SELL	$62.51 - $69.0 $42,881 - $47,334	-686 Reduced 0.7%	97,374 $6.17 Million
Q2 2019 Aug 12, 2019	BUY	$61.87 - $69.38 $815,137 - $914,081	13,175 Added 15.52%	98,060 $6.63 Million
Q1 2019 May 15, 2019	SELL	$62.53 - $70.05 $897,618 - $1.01 Million	-14,355 Reduced 14.46%	84,885 $5.52 Million
Q4 2018 Feb 13, 2019	SELL	$60.54 - $79.0 $78,459 - $102,384	-1,296 Reduced 1.29%	99,240 $6.21 Million
Q3 2018 Nov 13, 2018	SELL	$71.28 - $78.92 $2.93 Million - $3.25 Million	-41,137 Reduced 29.04%	100,536 $7.76 Million
Q2 2018 Aug 14, 2018	SELL	$64.88 - $75.68 $831,177 - $969,536	-12,811 Reduced 8.29%	141,673 $0
Q1 2018 May 10, 2018	BUY	$72.84 - $88.8 $1.69 Million - $2.07 Million	23,256 Added 17.72%	154,484 $11.6 Million
Q4 2017 Feb 14, 2018	SELL	$71.15 - $83.52 $1.09 Million - $1.28 Million	-15,288 Reduced 10.43%	131,228 $9.4 Million
Q3 2017 Nov 14, 2017	BUY	$72.11 - $85.47 $10.6 Million - $12.5 Million	146,516	146,516 $11.9 Million

Others Institutions Holding GILD

# of Institutions

1,923

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $113B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Natixis Advisors, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Natixis Advisors, L.P. with notifications on news.

Account

Natixis Advisors, L.P. Gilead Sciences, Inc. Transaction History